{"id":587633,"date":"2023-08-23T00:00:00","date_gmt":"2023-08-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2023-biopharma-asthma-access-reimbursement-us-2023\/"},"modified":"2026-08-28T11:31:18","modified_gmt":"2026-08-28T11:31:18","slug":"acreim0002-2023-biopharma-asthma-access-reimbursement-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2023-biopharma-asthma-access-reimbursement-us-2023\/","title":{"rendered":"Asthma | Access &#038; Reimbursement | US | 2023"},"content":{"rendered":"<p><strong>Market outlook<\/strong><\/p>\n<p>The dynamics within the LABA\/ICS FDC, LAMA, LABA\/LAMA\/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA\/ICS FDCs (e.g., GlaxoSmithKline\u2019s Advair, AstraZeneca\u2019s Symbicort) will likely decline further as new generic \/ branded generic agents continue to launch. In addition, the entrance of LABA\/LAMA\/ICS FDCs will create uptake challenges for Boehringer Ingelheim\u2019s Spiriva. A novel biologic (Amgen \/ AstraZeneca\u2019s tezepelumab) could compete with existing asthma biologics (e.g., GSK\u2019s Nucala, AstraZeneca\u2019s Fasenra) for certain subpopulations with severe refractory asthma. The entry of a novel SABA\/ICS FDC could affect the uptake of SABA reliever therapies, especially among patients with mild \/ intermittent asthma. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging asthma agents will face increasing challenges as they strive to retain\/gain favorable formulary position and market uptake.<\/p>\n<p><strong>Questions answered<\/strong>\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\u2022Which key asthma therapies (e.g., Roche \/ Novartis\u2019s Xolair, Sanofi \/ Regeneron\u2019s Dupixent) have favorable formulary placement, and how do payers manage the use and costs of these therapies?<\/p>\n<p>\u2022How do reimbursement restrictions affect physicians\u2019 prescribing of LABA\/ICS FDCs, Spiriva, Trelegy, and biologics to their asthma patients?<\/p>\n<p>\u2022How do payers \/ physicians expect emerging branded and generic \/ branded generic versions of market-leading LABA\/ICS FDCs (e.g., AB-rated generics of Advair and Symbicort) and other inhaled therapies to affect access to \/ prescribing of current branded therapies?<\/p>\n<p>\u2022How do physicians anticipate using emerging biologics, SABA\/ICS FDCs (i.e., AstraZeneca\u2019s PT-027 [albuterol \/ budesonide FDC]), and LABA\/LAMA\/ICS FDCs (i.e., AstraZeneca\u2019s Breztri), and how do payers expect to cover these therapies on commercial plans?<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>U.S. Access &#038; Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment.\u00a0 Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-587633","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/587633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=587633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}